ABSTRACT

Insulin pumps are commonly used for intensive insulin therapy to treat type 1 diabetes in adults and youth. Insulin pump technologies have advanced dramatically in the last several years to integrate with continuous glucose monitors (CGM) and incorporate control algorithms. These control algorithms automate some insulin delivery in response to the glucose information received from the CGM to reduce the occurrence of hypoglycemia and hyperglycemia and improve overall glycemic control. The t:slim X2 insulin pump system became commercially available in 2016. It is an innovative insulin pump technology that can be updated remotely by the user to install new software onto the pump device as new technologies become available. Currently, the t:slim X2 pairs with the Dexcom G6 CGM and there are two advanced software options available: Basal-IQ, which is a predictive low glucose suspend (PLGS) technology, and Control-IQ, which is a Hybrid Closed Loop (HCL) technology. This paper will describe the different types of advanced insulin pump technologies, review how the t:slim X2 insulin pump works, and summarize the clinical studies leading to FDA approval and commercialization of the Basal-IQ and Control-IQ technologies.

摘要

胰岛素泵通常用于强化胰岛素治疗，以治疗成人和青年人的1型糖尿病。在过去的几年中，胰岛素泵技术取得了巨大的进步，可以与连续血糖监测仪（CGM）集成在一起并整合控制算法。这些控制算法响应于从CGM接收到的葡萄糖信息，自动执行一些胰岛素输送，以减少低血糖和高血糖的发生，并改善总体血糖控制。t：slim X2胰岛素泵系统于2016年投入商业使用。这是一种创新的胰岛素泵技术，用户可以对其进行远程更新，以便在新技术出现时在泵设备上安装新软件。目前，t：slim X2与Dexcom G6 CGM配对，并且有两个高级软件可供选择：Basal-IQ，它是一种预测性的低葡萄糖悬浮（PLGS）技术，而Control-IQ是一种混合闭环（HCL）技术。本文将描述先进胰岛素泵技术的不同类型，回顾t：slim X2胰岛素泵的工作原理，并概述导致FDA批准和Basal-IQ和Control-IQ技术商业化的临床研究。